Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Zogenix logo — Developing innovative CNS and pain therapies that significan...

Zogenix

Developing innovative CNS and pain therapies that significantly address unmet medical needs.

Founded 2006 201-500 employees Post-IPO Debt Total: $1.52B Biotechnology, Health Care +1

General Information

Company Name Zogenix
Founded Year 2006
Employees 201-500
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Zogenix. To contact Zogenix, visit zogenix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Zogenix compare?

A PDF of Zogenix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Zogenix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Zogenix

Zogenix is a biotechnology and pharmaceutical company that was founded in 2006. The company's mission is reflected in its slogan, "Developing innovative CNS and pain therapies that significantly address unmet medical needs." Zogenix is dedicated to developing and bringing to market innovative therapies for central nervous system (CNS) disorders and pain management, with a specific focus on addressing significant unmet medical needs or improving upon current treatment options. The company is presently advancing two exclusive product candidates through the final stages of development for CNS disorders and pain relief. The first product, sumatriptan DosePro™, provides a needle-free subcutaneous delivery of sumatriptan to treat acute migraine. The second product, ZX002, is a novel controlled-release formulation of hydrocodone designed to manage chronic pain. Zogenix recently received a $230.00M Post-IPO Debt investment on 22 September 2020, indicating strong investor confidence in the company's potential. The details of the investors involved in the most recent funding round are not specified. Overall, Zogenix's commitment to addressing unmet medical needs in CNS disorders and pain relief, along with its recent substantial investment, positions the company as a promising player in the biotechnology and pharmaceutical industries.

Business keywords: pharmaceuticals, CNS disorders, pain management, migraine treatment, hydrocodone formulation, drug delivery, specialized pharmaceuticals, sumatriptan, needle-free delivery, controlled-release formulation, chronic pain management

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $230.00M -
22 Sep 2020
Post IPO Equity $230.25M -
03 Mar 2020
Post IPO Equity $312.00M -
07 Aug 2018
Post IPO Equity $288.94M -
02 Oct 2017
Post IPO Equity $69.00M -
05 Nov 2016
Post IPO Equity $98.33M -
30 Jul 2015
Post IPO Equity $60.00M -
16 Sep 2011
Post IPO Debt $30.00M 1
HealthCare Royalty Partners
HealthCare Royalty Partners
30 Jun 2011
Debt Financing $35.00M 2
Silicon Valley Bank, Oxford Finance LLC
13 Jul 2010
Venture Round $15.00M 7
Abingworth Domain Associates Scale Venture Partners
Abingworth, Domain Associates +5
13 Jul 2010

View All 15 Funding Rounds

Zogenix Alternatives & Competitors

View All Alternatives
Zogenix vs
Scilex Holding Company
Scilex Holding Company United States

Striving to Revolutionize the World of Non-Opioid Pain Management

Post-IPO Debt
104 employees
Health Care, Pharmaceutical
Zogenix vs
Axxia Pharmaceuticals
Axxia Pharmaceuticals

Innovative polymeric implants for precise, long-term pain relief therapy.

Seed
2 employees
Biotechnology, Health Care
Zogenix vs
NovaXS Biotech Corp.
NovaXS Biotech Corp. United States

Delivering future therapeutics within your grasp.

Seed
5 employees
Biotechnology, Health Care
View all alternatives

FAQ About Zogenix

Developing innovative CNS and pain therapies that significantly address unmet medical needs.
Zogenix was founded in 2006.
Zogenix operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on pharmaceuticals, CNS disorders, pain management and migraine treatment.
Zogenix has approximately 201-500 employees.
Zogenix has completed 15 funding rounds, raising a total of $1.52B. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to Zogenix include Scilex Holding Company, Axxia Pharmaceuticals, NovaXS Biotech Corp., Strategic Science & Technologies, Plumb Pharmaceuticals, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Zogenix and Scilex Holding Company are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Zogenix, https://bouncewatch.com/company/zogenix, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes